


Pharmaceuticals & Biotechnology | Small Cap
Supriya Lifescience Ltd demonstrates a strong financial standing, particularly in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases impressive growth in revenue, operating profit, and earnings per share. Its ability to cover interest and dividends is also remarkable. Profitability metrics, including gross profit margin, return on capital employed, and return on assets, reflect solid performance. However, efficiency ratios indicate potential challenges in fixed asset, inventory, and capital turnover. While liquidity is generally healthy, there's room to optimize cash management. Overall, Supriya Lifescience exhibits a robust and promising financial profile, balanced by the need for improved asset utilization.
Supriya Lifescience Ltd demonstrates a strong financial standing, particularly in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases impressive growth in revenue, operating profit, and earnings per share. Its ability to cover interest and dividends is also remarkable. Profitability metrics, including gross profit margin, return on capital employed, and return on assets, reflect solid performance. However, efficiency ratios indicate potential challenges in fixed asset, inventory, and capital turnover. While liquidity is generally healthy, there's room to optimize cash management. Overall, Supriya Lifescience exhibits a robust and promising financial profile, balanced by the need for improved asset utilization.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
34.29
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
34.29
P/B RATIO
5.98
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
8.57
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
3.11
EV/EBITDA RATIO
23.04
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹890.85 as on Aug 6, 2026.
The company demonstrates excellent growth across various metrics, including revenue, operating profit, earnings per share, assets, and net income. This consistent growth indicates strong market performance and effective management strategies. This growth indicates the company is doing well.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 35.55 | -13.02 | 23.64 | 22.11 | 18.97 |
| Operating Profit Growth Rate | 23.7 | -39.72 | 36.43 | 48.3 | 12.64 |
| Earnings Per Share (EPS) Growth | 11.66 | -40.77 | 32.5 | 57.77 | 11.26 |
| Asset Growth Rate | 65.17 | 11.56 | 12.32 | 20.74 | 22.03 |
| Net Income Growth Rate | 22.58 | -40.79 | 32.22 | 57.98 | 11.17 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 13 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 14 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 15 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 16 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 17 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral